Document Classification

Section Type: RESULTS

Text: At 15 weeks, adjusted mean 25OHD was 26 % higher (p < 0. 001, ALN + D versus ALN), the adjusted relative risk (RR) of 25OHD < 15 ng/mL (primary endpoint) was reduced by 64 % (incidence 11 % vs. 32 % ; RR = 0. 36 ; 95 % CI : 0. 27 to 0. 48 [p < 0. 001]), and the RR of 25OHD < 9 ng/mL (a secondary endpoint) was reduced by 91 % (1 % vs. 13 % ; RR = 0. 09 ; 95 % CI : 0. 03 to 0. 23 [p < 0. 001]).